All-cause mortality in pimavanserin and atypical antipsychotic users with Parkinson’s disease in Medicare
Objective: To assess all-cause mortality in Medicare beneficiaries with Parkinson’s disease (PD) receiving pimavanserin or atypical antipsychotics (AAs). Background: In PD patients, the lifetime prevalence…A pilot study on the shift from rasagiline to safinamide in fluctuating Parkinson’s disease patients
Objective: Here we investigated the consequences of the shift from rasagiline (RS) to SF in fluctuating PD patients. To this end, we selected patients from…A monocentric experience of Apomorphine pump follow-up on PD patients: The Optipump Cohort
Objective: The goal of this study is to describe the factors that may have an impact on Continuous Subcutaneous Apomorphine Infusion (CSAI) therapy initiation and…Towards a scoring system to distinguish early parkinsonian variant of multiple system atrophy from Parkinson’s disease
Objective: To develop a clinical score to distinguish between the parkinsonian variant of multiple system atrophy (MSA-P) and Parkinson’s disease (PD). Background: The differential diagnosis…Is brain perfusion a differentiating factor between Parkinson’s Disease (PD) and Progressive Supranuclear Palsy – Parkinsonism Predominant (PSP-P)?
Objective: Parkinson’s Disease – Postural Instability Gait Disorder (PD-PIGD) and Progressive Supranuclear Palsy – Parkinsonism Predominant (PSP-P) are entities affected by difficulties in differentiation in…Chromogranin B in cerebrospinal fluid as a novel biomarker for Progressive supranuclear palsy
Objective: To identify the biomarker associated with progressive supranuclear palsy (PSP) for better understanding of a pathophysiology and clinical diagnosis. Background: PSP is one of…Clinical and nuclear neuroimaging features of Parkinson’s disease with dysphagia
Objective: The clinical and neuroimaging factors associated with dysphagia were investigated in this retrospective data of Parkinson's disease (PD) patients. Background: PD can cause dysphagia…Management practices and long-term follow up of pediatric functional (psychogenic) movement disorder at a tertiary care center
Objective: We evaluated management practices and compared efficacy of specific interventions on remission of symptoms of functional movement disorder (FMD) in our pediatric population. Background: Current recommendations of managing FMD revolve…Effects of Different Side-of-onset on Symptoms, Progression, and Prognosis in Parkinson’s Disease
Objective: We conducted an ambispective cohort study, with the largest number of involved patients for now, to assess whether the different side-of-onset could affect the…The Feasibility of Using of the Non-Medication in the Treatment of Post-Stroke Vascular Parkinsonism
Objective: Vascular parkinsonism is an infrequent but unpleasant complication of cerebrovascular disease, in particular brain stroke. Background: The effect of the complex treatment with non-medication…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.